FDA Brief

Warning letters Drugs

FDA warning letter to

Nature's Highway

High riskIssued Mar 28, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned CBD seller Nature's Highway for selling unapproved drugs claimed to treat or prevent COVID-19.

What happened

FDA reviewed the company's website on February 17, 2022, and the FTC reviewed it on March 7, 2022; both also looked at a linked Facebook page that sends buyers to the site. The letter says the sites offer hemp-derived CBD products with statements that CBD may help treat, prevent, or ease COVID-19, which makes the products unapproved new drugs and misbranded. No manufacturing inspection took place.

What FDA found

  1. The company sells CBD products as drugs for COVID-19 without FDA approval.

    Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The product labels and websites lack the information the law requires for drugs, so the products are misbranded.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Shipping these unapproved and misbranded products across state lines is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertises that its products prevent, treat, or cure disease without solid scientific evidence to back the claims.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. Deceptive claims about treating, curing, preventing, or easing COVID-19 can bring civil penalties of up to $46,517 per violation.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to stop selling the unapproved COVID-19 products immediately and, within 48 hours, email a description of the corrective steps taken and how it will prevent repeat violations. The FTC separately asks for an email within 48 hours certifying that the unsupported claims have stopped.

Who should pay attention

  • CBD and supplement brands making health claims on their websites
  • online sellers marketing products against COVID-19
  • retailers and marketplaces carrying hemp-derived CBD products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk